Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Triboelectric Nanogenerator-Driven Laser Ablation Electrospray Ionization Enables Neutral Lipid Ionization and in Situ Double-Bond Localization.
Journal: Journal of the American Society for Mass Spectrometry
Published: April 15, 2026
A 5'-(R)-CH3-substituted 5-fluoro-2'-deoxyuridine monophosphate reduces off-target toxicities while maintaining efficacy in a colorectal cancer model.
Journal: The Journal of pharmacology and experimental therapeutics
Published: September 05, 2025
A Spatial Metabolomics Annotation Workflow Leveraging Cyclic Ion Mobility and Machine Learning-Predicted Collision Cross Sections.
Journal: Journal of the American Society for Mass Spectrometry
Published: May 21, 2025
Next-Generation Lipid Prodrugs Orally Deliver Tenofovir via Enhanced Chylomicron Incorporation.
Journal: ACS pharmacology & translational science
Published: April 01, 2025
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Journal: ACS pharmacology & translational science
Published: June 11, 2024
A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy.
Journal: bioRxiv : the preprint server for biology
Published: April 08, 2024
Discovery of 5'-Substituted 5-Fluoro-2'-deoxyuridine Monophosphate Analogs: A Novel Class of Thymidylate Synthase Inhibitors.
Journal: ACS pharmacology & translational science
Published: December 29, 2022
Machine Learning-Enabled Renal Cell Carcinoma Status Prediction Using Multiplatform Urine-Based Metabolomics.
Journal: Journal of proteome research
Published: June 23, 2021
Liver-Targeting Class I Selective Histone Deacetylase Inhibitors Potently Suppress Hepatocellular Tumor Growth as Standalone Agents.
Journal: Cancers
Published: September 25, 2020
The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression.
Journal: Translational oncology
Published: February 03, 2020
Last Updated: 09/26/2026